UCSF Search Toolbar
UCSF Radiation Oncology
Search

Prostate Cancer


Study Title

A Randomized phase II trial of Hypofractionated Radiotherapy for Favorable Risk Porstate Cancer.

Prinicipal Investigators

Study Number

RTOG 0938

Status of Trial

Open

Why is this study being done?

The purpose of this study is to compare the effects, good and/or bad, of two methods of delivering high dose radiation to the prostate. Standard radiation therapy can involve daily treatment for several weeks, totaling up to approximately 40 treatments. In this study, we will use a more recent radiation therapy called “intensity modulation radiation therapy (IMRT) which allows safer delivery of higher than standard daily doses of radiation. You will receive a total of 5 treatments OR a total of 12 treatments over about two and a half weeks.

We will test whether the 5-treatment schedule or the 12-treatment schedule gives similar results or if one works better than theother in terms of the side effects on bowel, bladder, and sexual function. We will also compare these treatments to standard radiation therapy and compare the changes in quality of life for both treatment groups.

Eligibile patients must have the following:

· Biopsy confirmed diagnosis of adenocarcinoma of the prostate within 365 days of randomization
· Gleason scores 2-6 within 365 days of randomization
· Clinical stage T1-2a
· Prostate-specific antigen (PSA) < 10 ng/mL


Patients are randomized to one of the two following treatment schedules.
Arm I: Patients undergo hypofractionated radiotherapy using intensity-modulated radiation therapy (IMRT), cyberknife, or protons twice a week for approximately 212 weeks (36.25 Gy total).

Arm II: Patients undergo hypofractionated radiotherapy using IMRT, cyberknife, or protons once a day, 5 days a week, for approximately 212 weeks (51.6 Gy total).

 

Contact

Marilyn Robinson, CCRP
Clinical Research Coordinator-Superviso
r
UCSF Department of Radiation Oncology
Helen Diller Family Comprehensive Cancer Center, Suite H1031
1600 Divisadero Street, Box 1708
San Francisco, CA 94143-1708 (USPS), Deliveries: 94115 for Fed
Ex/UPS/Courier

Voice: 415/353.4294
Fax: 415/353.7371
Voice: 415/443.6604
Email: robinsonmg@radonc.ucsf.edu


Study Title

Pre-Operative Gleason Score and PSA and Clinical Stage in Predicting the Risk of Failure in Patients Undergoing Radiation Therapy for Localized Prostate Cancer

Prinicipal Investigators

Study Number

N/A

Status of Trial

Open

Why is this study being done?

Mack Roach III, M.D, from the Department of Radiation Oncology, is conducting a review of your chart to determine the effectiveness of your radiation treatment and whether he can identify factors that may affect outcomes.

You are being asked to participate in this study because you were treated with radiation therapy for prostate cancer at the University of California at San Francisco, San Francisco General Hospital and San Francisco Veterans Administration Medical Center.

 

Contact

Marilyn Robinson, CCRP
Clinical Research Coordinator-Superviso
r
UCSF Department of Radiation Oncology
Helen Diller Family Comprehensive Cancer Center, Suite H1031
1600 Divisadero Street, Box 1708
San Francisco, CA 94143-1708 (USPS), Deliveries: 94115 for Fed
Ex/UPS/Courier

Voice: 415/353.4294
Fax: 415/353.7371
Voice: 415/443.6604
Email: robinsonmg@radonc.ucsf.edu


Study Title

Prospective Phase II Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Adenocarcinoma Following External Beam Radiotherapy.

Prinicipal Investigators

Study Number

RTOG 0526

Status of Trial

Open

Why is this study being done?

The purpose of this study is to evaluate the safety and effectiveness of brachytherapy (radiation seed implants) as treatment for prostate cancer that has come back in the prostate after external radiotherapy.  The study will examine the side effects of the implants as well as the ability of the implants to get rid of the cancer.

It is important for you to realize that sometimes when prostate cancer comes back in the prostate after radiation, it may be very slow growing and may not cause you symptoms or problems for years.  Sometimes just monitoring your condition and not undergoing repeat treatment is appropriate.  The treatment offered in this study may cause side effects.  The side effects are discussed in this consent form, and you should read that section carefully and discuss it with your study doctor.

 

Contact

Marilyn Robinson, CCRP
Clinical Research Coordinator-Superviso
r
UCSF Department of Radiation Oncology
Helen Diller Family Comprehensive Cancer Center, Suite H1031
1600 Divisadero Street, Box 1708
San Francisco, CA 94143-1708 (USPS), Deliveries: 94115 for Fed
Ex/UPS/Courier

Voice: 415/353.4294
Fax: 415/353.7371
Voice: 415/443.6604
Email: robinsonmg@radonc.ucsf.edu


Study Title

Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) with a GnRH Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT with a GnRH Agonist and TAK-700 for Men with High Risk Prostate Cancer.

Prinicipal Investigators

Study Number

RTOG 1115

Status of Trial

Open

Why is this study being done?

PURPOSE: This randomized phase III trial is studying the use of hormone therapy, including TAK-700, together with radiation therapy in treating patients with prostate cancer.

Androgens can cause the growth of prostate cancer cells. Drugs, such as steroid 17alpha-monooxygenase TAK-700, when used with other hormone therapy, may lessen the amount of androgens made by the body. Radiation therapy uses high energy x rays to kill tumor cells. This may be an effective treatment for prostate cancer when combined with hormone therapy. Studying quality-of-life in patients having cancer treatment may help identify the intermediate- and long-term effects of treatment on patients with prostate cancer.
Eligible patients:

Histologically confirmed diagnosis of adenocarcinoma of the prostate within 180 days prior to registration at high risk for recurrence as determined by one of the following combinations (risk group):

Gleason Score (GS) ≥ 9, PSA ≤ 150 ng/mL, any T stage
GS ≥ 8, PSA < 20 ng/mL, T stage ≥ T2
GS ≥ 8, PSA ≥ 20-150 ng/mL, any T stage
GS ≥ 7, PSA ≥ 20-150 ng/mL, any T stage


Patients are randomized to one of the two following treatments. The patient nor their doctor can choose which treatment.

Standard treatment Arm I
Patients receive standard androgen suppression (AS) with a luteinizing hormone-releasing hormone (LHRH) agonist (such as leuprolide, goserelin, buserelin, or triptorelin) for 24 months from initiation and oral (PO) antiandrogen (such as flutamide or bicalutamide) beginning 2 months prior and for the duration of radiation therapy (RT).

Experimental: Arm II
Patients receive the same standard AS with a LHRH agonist and oral antiandrogen as in arm 1. Patients also receive steroid 17alpha-monooxygenase TAK-700 (TAK-700) PO twice daily (BID) for 2 years.

Contact

Marilyn Robinson, CCRP
Clinical Research Coordinator-Superviso
r
UCSF Department of Radiation Oncology
Helen Diller Family Comprehensive Cancer Center, Suite H1031
1600 Divisadero Street, Box 1708
San Francisco, CA 94143-1708 (USPS), Deliveries: 94115 for Fed
Ex/UPS/Courier

Voice: 415/353.4294
Fax: 415/353.7371
Voice: 415/443.6604
Email: robinsonmg@radonc.ucsf.edu


Study Title

A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer.

Prinicipal Investigators

Study Number

RTOG 0924

Status of Trial

Open

Why is this study being done?

RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens. Radiation therapy uses high-energy x-rays to kill tumor cells.

PURPOSE: This randomized phase III trial studies androgen-deprivation therapy and radiation therapy in treating patients with prostate cancer.

If you agree to participate in this study, you will receive one of these 2 treatments.

 

Contact

Marilyn Robinson, CCRP
Clinical Research Coordinator-Superviso
r
UCSF Department of Radiation Oncology
Helen Diller Family Comprehensive Cancer Center, Suite H1031
1600 Divisadero Street, Box 1708
San Francisco, CA 94143-1708 (USPS), Deliveries: 94115 for Fed
Ex/UPS/Courier

Voice: 415/353.4294
Fax: 415/353.7371
Voice: 415/443.6604
Email: robinsonmg@radonc.ucsf.edu